ArticleThe American journal of case reports2026
Fatal Cardiomyopathy Secondary to Seronegative Immune-Mediated Necrotizing Myopathy: A Case Report.
Article in The American journal of case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Seronegative Immune-Mediated Necrotizing Myopathy: An Overview for Optimal Clinical Management.Current rheumatology reports · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND Idiopathic inflammatory myopathies (IIM) are disorders of autoimmune inflammation of muscle tissue. IIM subtypes include polymyositis, dermatomyositis, inclusion body myositis, and immune-mediated necrotizing myopathy (IMNM); which can be further subdivided based on serology. These disorders primarily affect skeletal muscle, and cardiac involvement is uncommon. We present a case of a patient with progressive cardiomyopathy as a rare complication of seronegative IMNM. CASE REPORT A previously healthy 35-year-old man presented with proximal muscle weakness and myalgias. Initial workup revealed elevated creatinine kinase and inflammatory markers, with magnetic resonance imaging findings of proximal muscle inflammation; muscle biopsy was diagnostic of IMNM. Serologic testing was negative for anti-SRP and anti-HMGCR, consistent with seronegative IMNM. Initial treatment included high-dose glucocorticoids, methotrexate, and intravenous immunoglobulin. He subsequently developed acute heart failure complicated by ventricular tachycardia. Additional treatment modalities included rituximab, mycophenolate mofetil, and cyclophosphamide. Cardiac positron emission tomography demonstrated an inflammatory myocardial process, and endomyocardial biopsy demonstrated interstitial fibrosis with macrophages. Despite treatment and advanced cardiac therapies, the patient developed progressive cardiogenic shock and cardiac arrest, ultimately resulting in death. CONCLUSIONS This is a case of fatal, treatment refractory cardiomyopathy secondary to seronegative IMNM. In patients with seronegative IMNM, clinical cardiac involvement likely conveys a poor prognosis. It is not understood what treatments are effective in this patient population, presenting opportunities for further study.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.